MAPT and Alzheimer disease: At the level of clinical applicability, Donanemab/Lecanemab requires strict screening of early AD patients (Aβ + and Tau below medium), high treatment costs (such as Lecanemab annual cost > USD 26,000) and reliance on biomarker monitoring (van Dyck et al., 2023).